Every material Form 8-K GeoVax Labs, Inc. has filed with the SEC since August 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
GeoVax Labs said on November 5, 2026 that its Board terminated David A. Dodd as President and Chief Executive Officer, effective immediately, and treated the termination as for Cause under his 2018 Employment Agreement. Dodd remains a director and Chairman, and the company does not intend to pay the severance he would receive without Cause, but he may dispute the determination, which could lead to severance and option-vesting costs.
Termination of President and CEO David A. Dodd effective immediately, dated November 5, 2026; he remains a director and Chairman
Board cites Dodd's refusal to comply with Board-approved directives as the basis for Cause
Company does not intend to pay severance, including a cash payment of three times base salary and target bonus, or full option vesting; Dodd may dispute and claim these
Company states the termination is unrelated to its business operations, financial results, or previously filed financial statements
GeoVax entered a revolving loan agreement dated October 25, 2026 with Bowery Consulting Group Inc. for up to $1 million outstanding at one time, at 12% interest, with no amount borrowed as of the filing. The lender can refuse any drawdown at its sole discretion, and either party can terminate the commitment. Five directors resigned effective October 23, 2026, and three lender-designated nominees now make up three of the five board seats, so shareholders should note both the costly, contingent financing and the shift in board control.
Loan facility of up to $1 million at 12% per annum, due on the first anniversary of closing; no amount borrowed as of the filing date
Lender may refuse any drawdown in its sole discretion, and either party may terminate the commitment at any time
Directors Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan and John Spencer, Jr. resigned effective October 23, 2026; Steven Brown, Tyler O'Brien and Manpreet Uppal were appointed as lender nominees
Nominees automatically resign if the initial public equity offering is not closed within ten business days after the S-1 becomes effective, or if at least $10 million in total financing is not completed by December 31, 2026
GGeoVax Labs said it has requested a Nasdaq Hearings Panel appeal of a delisting determination it received on August 27, 2026, over the minimum bid price requirement, with a hearing scheduled for October 13, 2026. The company says its stock should keep trading on the Nasdaq Capital Market under GOVX at least through that period, and it reaffirmed its focus on the GEO-MVA vaccine program and Gedeptin.
Nasdaq delisting determination received August 27, 2026, relating to the minimum bid price requirement under Listing Rule 5550(a)(2)
Hearing before the Nasdaq Hearings Panel scheduled for October 13, 2026
Hearing request has stayed any suspension or delisting action; GOVX expected to keep trading at least through that period
GeoVax plans to present a compliance plan to regain and maintain listing standards
GeoVax Labs received a Nasdaq Staff Determination Letter on August 27, 2026, stating Nasdaq will delist its common stock because the bid price stayed below $1.00 and the company is not eligible for the customary 180-day compliance period after its January 2026 reverse split. The company plans to request a hearing before the Nasdaq Hearings Panel, which would stay further action and keep the stock trading during the appeal, but the filing says there is no assurance the panel will grant continued listing.
Nasdaq determined the closing bid price was below $1.00 for 30 consecutive business days from July 16, 2026 through August 26, 2026.
The company effected a 1-for-25 reverse stock split on January 12, 2026, which made it ineligible for the 180-day compliance period.
Absent a timely hearing request, trading is expected to be suspended at the opening of business on September 8, 2026; the hearing request deadline is September 3, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GeoVax Labs, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →